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Abstract
Background:  Although a randomized trial represents the most rigorous method of evaluating a
medical intervention, some interventions would be extremely difficult to evaluate using this study
design. One alternative, an observational cohort study, can give biased results if it is not possible
to adjust for all relevant risk factors.
Methods:  A recently developed and less well-known alternative is the paired availability design
for historical controls. The paired availability design requires at least 10 hospitals or medical
centers in which there is a change in the availability of the medical intervention. The statistical
analysis involves a weighted average of a simple "before" versus "after" comparison from each
hospital or medical center that adjusts for the change in availability.
Results:  We expanded requirements for the paired availability design to yield valid inference. (1)
The hospitals or medical centers serve a stable population. (2) Other aspects of patient
management remain constant over time. (3) Criteria for outcome evaluation are constant over
time. (4) Patient preferences for the medical intervention are constant over time. (5) For hospitals
where the intervention was available in the "before" group, a change in availability in the "after
group" does not change the effect of the intervention on outcome.
Conclusion:  The paired availability design has promise for evaluating medical versus surgical
interventions, in which it is difficult to recruit patients to a randomized trial.
Background
In terms of avoiding bias, the most rigorous method for
evaluating a medical intervention is the randomized con-
trolled trial. However, many clinical investigators are
unable to conduct a randomized trial because of exces-
sive cost or required effort or difficulty overcoming
strongly held beliefs among health care providers or pa-
tients. In these situations, a clinical investigator may
consider a design and analysis based on observational
data (Table 1).
One common method of inference from observational
data is the cohort study with an adjustment for risk fac-
tors using, for example, regression models [1] and pro-
pensity scores [2]. In some situations, estimates from
high-quality cohort studies have been similar to those
from randomized trials [2][3][4][5]. However there are
some notable exceptions, including studies of the effect
of beta-carotene on cardiovascular mortality [6][7], the
effect of hormone therapy on the rate of cardiovascular
disease [8], the effect of epidural analgesia on the proba-
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bility of Cesarean section [9], the effect of beta-blockers
on mortality [10], and the effect of aspirin on the risk of
colorectal cancer [11]. Some of the discrepancy between
the results of these high quality cohort studies and rand-
omized trials may be explained by differences in the in-
tervention, patient population, or duration of follow-up.
Nevertheless, a major reason for bias with cohort studies
is the failure to adjust for all factors related the receipt of
intervention and outcome. This failure may be due to the
inability to identify or collect the necessary data, or the
difficulty measuring or quantifying subjective factors
such as clinical judgment. For a fuller discussion of how
an omitted factor related to receipt of intervention and
outcome can bias results in a cohort study but not a ran-
domized trial see Baker and Kramer [12].
Methods
An alternative and less widely known approach is the
paired availability design for historical controls
[9][13][14]. As we describe in more detail, the paired
availability design consists of comparing outcomes in
multiple hospitals or medical centers before versus after
a change in availability of a medical intervention. To ad-
just for different changes in availability among the hos-
pitals or medical centers, the test statistic for each
hospital or medical center is the difference in outcome
before and after the change in availability divided by the
change in the fraction of patients who receive the inter-
vention. These test statistics are combined in a meta-
analysis, which weights the statistic from each hospital
according to the reciprocal of the variance, a quantity
that depends on sample size and the change in availabil-
ity.
The paired availability design avoids many of the biases
of analyses based on traditional historical controls. With
traditional historical controls, investigators compare
outcome among subjects who receive a new intervention
with outcome among a previous group of subjects who
received the standard intervention. Selection bias often
arises because subjects who receive the new intervention
are typically not comparable to subjects who received the
standard intervention [15]. The paired availability design
reduces selection bias because the comparison is be-
tween all subjects (those who received the intervention
and those who did not) before the change in availability
and all subjects (those who received the intervention and
those who did not) after the change in availability. Thus
the intervention is the availability of treatment, instead
of the receipt of treatment. If the sample of all subjects
eligible for intervention is comparable before and after
the change in availability, one can obtain an unbiased es-
timate of the effect of a change in availability by compar-
ing outcome among all subjects before the change in
availability with the outcome among all subjects after the
change in availability. This is analogous to obtaining an
unbiased estimate of the effect of intent-to-treat by com-
paring outcomes among all subjects in each arm of a ran-
domized trial subject to noncompliance.
For both the paired availability design and randomized
trials subject to noncompliance, the ideal goal is an unbi-
ased estimate of the effect of receipt of treatment. If cer-
tain requirements hold, which we discuss, a simple
adjustment gives an unbiased estimate of the effect of re-
ceipt of treatment in the paired availability design. Simi-
larly, in certain situations involving randomized trials
with noncompliance, such as switching interventions im-
mediately after randomization, a similar adjustment also
yields an unbiased estimate of the effect of receipt of
treatment [16][17]. Readers interested in a formal math-
ematical statement of these requirements and how they
Table 1: Comparison of Several Methods of Evaluating a Medical Intervention
Method Strengths Weaknesses
Randomized controlled trial 1. No temporal bias 1. Cost and effort
2. No selection bias 2. Recruitment
Observational cohort study 1. No temporal bias 1. Cost of data collection
2. Selection bias if an
important risk factor is
omitted or not
adequately quantified
Paired availability design 1. Lessens selection bias 1. Assumptions in Table 2BMC Medical Research Methodology 2001, 1:9 http://www.biomedcentral.com/1471-2288/1/9
give rise to the simple estimate should consult references
[9][13][14][16][17].
Results
To assist investigators who are contemplating a paired
availability design, we provide an expanded list of re-
quirements for valid inference as well as a simpler meth-
od of data analysis than previously discussed in the
literature.
Design
The paired availability design uses data collected in ei-
ther a prospective or retrospective manner, or a combi-
nation of the two. Although implementing a multi-center
study may initially appear burdensome, two mitigating
factors lessen the burden: (1) randomization is not re-
quired and (2) investigators need not collect data on risk
factors if the requirements hold. The requirements (to
follow) are most likely to hold when the time period for
the entire study is not too long. We recommend limiting
the total study duration to not more than two years, rec-
ognizing there may be exceptions due to patient accrual
rate, intervention, and outcome. If availability changes
gradually, it is often sufficient to split the data halfway
between the start of the "before" period and the end of
the "after" period; although more sophisticated statisti-
cal techniques can be employed [9]
The change in availability between the "before" and "af-
ter" periods can take different forms which do not affect
the design or analysis. With fixed availability, the inter-
vention is available to all subjects who arrive during a
certain time of day or day of the week. With random
availability, the intervention is available only if the nec-
essary personnel or equipment is available, which occurs
at random. In either case, subjects can decide whether or
not to undergo the intervention.
The study design has five requirements for making ap-
propriate inference: stable population, stable treatment,
stable evaluation, stable preference, and no effect of
availability on the effect of intervention (Table 2). Stable
population, treatment, and evaluation, are required for
appropriate inference in any medical study involving
comparisons over time. Stable preference and no effect
of availability on the effect of intervention, are needed to
adjust for differences in availability among hospitals or
medical centers.
Table 2: Requirements for Paired Availablity Design
Requirement Specific Criteria
Stable population 1. Hospital serves one geographic area or
is military medical center
2. No in- or out- migration
3. Eligibility criteria constant over time
4. No underlying change in prognosis
over time
Stable treatment 1. Other patient management constant
over time
Stable evaluation 1. Evaluation criteria constant over time
Stable preference 1. No publicized credible reports
2. No direct-to-consumer advertising
Effect of the intervention on outcome does 1. Effect of intervention does not depend
not change with a change in availability on when the intervention was given
(only applicable when some in "before" during the course of disease
group receive intervention) 2. No learning curve for the interventionBMC Medical Research Methodology 2001, 1:9 http://www.biomedcentral.com/1471-2288/1/9
The first requirement, stable population, is that the com-
position of subjects eligible for the intervention should
not change from the "before" to the "after" period in ways
that would affect outcome. This requirement would be
violated if subjects seek treatment because of the availa-
bility of the treatment under study. The assumption is
therefore violated if hospitals advertise the availability of
a new diagnostic test or medical intervention. In addi-
tion, each hospital or medical center should serve a well-
defined population with little in- or out- migration. Ex-
amples include the only hospital in a geographic region
or a military medical center. The presence of two or more
hospitals in a region could introduce bias if the new in-
tervention were available in only one hospital and it were
not possible to exclude from the analysis patients who
switched hospitals to undergo the new intervention. The
stable population requirement would also be violated by
changes in eligibility criteria over time. If eligibility is de-
termined by a medical diagnosis, the method of diagno-
sis must not change over time. Lastly the stable
population requirement would be violated if the underly-
ing prognosis of patients changed over time. For example
in a study of treatment for a viral infection which is
spreading through a population, the most susceptible
subjects would likely enter the trial first, which would vi-
olate the stable population requirement if they have the
worse prognosis after infection.
The second requirement, stable treatment, is that the pa-
tient management unrelated to the intervention is iden-
tical in the "before" and "after" groups. Thus, in studying
the effect of epidural analgesia on the probability of Cae-
sarian section, other forms of obstetric management
should be constant over time. Similarly, in studying the
effect of an intense chemotherapeutic regimen for cancer
on survival, the type of antibiotic should not change of
over time, as new and more effective antibiotics could
lower treatment-related mortality irrespective of the ef-
ficacy of the anticancer regimen.
The third requirement, stable evaluation, is that the
method of evaluation is identical in the "before" and "af-
ter" groups. For example, the use of a new radiologic test
to stage cancer in the "after" group may artifactually im-
prove prognosis of each stage, independent of the thera-
py [18].
Because the paired availability design involves multiple
hospitals or medical centers, random violations of the
stable population, treatment, and evaluation require-
ments will tend to average out, and not affect the conclu-
sion. The main concern is with systematic violations. To
minimize systematic violations, if possible, a wide varie-
ty of hospitals or medical centers should be studied.
Table 3: Example of calculations from data in Baker and Lindeman [Reference 9]
hospital before" group data after group data estimate std error weight
n1 e1 P1 n2 e2 p2 y s w
1 116 .586 .172 103 .223 .184 -.033 .143 44
2 180 .290 .080 180 .440 .090 .067 .196 24
3 373 .131 .110 421 .587 .100 -.022 .048 208
4 1000 .100 .040 1000 .450 .050 .029 .026 313
5 1298 .000 .074 1084 .480 .065 -.019 .022 333
6 1919 .000 .275 2073 .316 .229 -.146 .044 225
7 3195 .010 .030 3733 .290 .031 .004 .015 365
8 4778 .008 .194 4859 .586 .190 -.006 .014 369
9 4685 .187 .149 6170 .551 .125 -.046 .015 352
10 8108 .467 .248 9918 .678 .280 .152 .031 288
11 11159 .328 .209 11869 .499 .209 .000 .031 288
n1 (n2) = number of subjects in "before" ("after") group. el (e2) = fraction of subjects in "before" ("after") group that had epdiural analgesia, p1 (p2) 
= fraction of subjects in "before" ("after") group that had a Cesarean section, y= estimated effect of epidural analgesia on the probability of Cesarean 
section = (p2-p1)/(e2-e1), s= standard error of y= square root of (p2 (1-p2))/n2 + p1 (1-p1)/n1) /(e2-e1)2, w* = weight used in random effects meta-
analysis. We computed the weights as follows. Let i index studies, so yi and si are the values of y and s for study i. It is convenient to define w1 = I/ 
si 2. Following DerSimonian and Laird [Reference 19], to compute v, the variance of the true effect among the k studies, we set v equal to the larger 
of (Q-(k-1)) / (Σ wi - Σ wi 2/Σ wi) and 0, where Q = Σ wi (yi - m)2, m = Σ yi wi/Σ wi. The random-effects weights are w* i= 1/(si 2 + v), and the summary 
statistic is y* = Σ yi w* i/Σ w* i, with standard error s* = square root of 1/Σ w* i. Following Proschan and Follman [reference 20], the 95% confidence 
interval is (y* - tk- s*, y*+ tk-1 s*), where tk-1 is the value of the 97 1/2 percentile of a t-distribution with k-1 degrees of freedom. In this example, k = 
11, Q = 50.1, v = .0025, m =-.007, s* = .019 y* = -.005, t10 = 2.23, y* = -.005 and the 95% confidence interval is (-.047, .037).BMC Medical Research Methodology 2001, 1:9 http://www.biomedcentral.com/1471-2288/1/9
The fourth requirement, stable preference, is strength-
ened in the absence of new information in the "after" pe-
riod that would change a subject's preference for the
medical intervention. This requirement could be violated
by a widely publicized report of a harmful side effect of
the new treatment, or direct-to-consumer advertising of
the intervention to consumers. To the best of our knowl-
edge, in the paired availability design to study the effect
of epidural analgesia on the probability of Cesarean sec-
tion, there were no credible reports of either detrimental
or beneficial side effects to the mother or fetus from epi-
dural analgesia and no relevant direct-to-consumer ad-
vertising. In contrast, if the media reported preliminary
results that radioactive seed implants had fewer side ef-
fects than previous approaches for treating prostate can-
cer, healthier subjects who care most about the side
effects may be more likely to request the new therapy
than less healthy subjects who only care if treatment re-
duces the risk of mortality.
The fifth requirement is that the effect of the interven-
tion on outcome does not change with a change in avail-
ability. Importantly, it applies only when there are some
subjects in the "before" group who undergo the interven-
tion. Mathematically the following two assumptions are
required to estimate method effectiveness [9][13][14].
(1) Subjects in the "before" group who undergo interven-
tion have comparable counterparts in the "after" group
who undergo intervention (which is justified by the other
requirements) and the effect of intervention is the same
in both groups, i.e. it does not depend on a change in
availability. (2) Subjects in the "after" group who do not
undergo the intervention have comparable counterparts
in the "before" group who do not undergo the interven-
tion (as justified by the other requirements) and the ef-
fect of no intervention is the same in both groups. By
definition no intervention is the same in the "before" and
"after" groups, so a change in availability of intervention
would have no bearing on (2). Thus the effect of a change
in availability on the effect of the intervention only per-
tains to (1), where subjects in the "before" group undergo
intervention.
The fifth requirement would be violated if increased
availability caused some subjects to undergo the inter-
vention sooner in the course of the disease, changing
prognosis. The fifth requirement would also be violated
if there were a learning curve with new intervention,
such as a surgical technique that improves with the
number of procedures. If such violations are likely, the
design should be restricted to hospitals or medical cent-
ers where no subjects in the "before" group received the
intervention.
Baker and Lindeman provided a formula to calculate the
required the number of hospitals or medical centers to
achieve sufficient power for hypothesis testing [13].
However, the formula may be difficult to use if the re-
quired information on the likely variability of an effect
over hospitals or medical centers is not readily available.
In such situations, as a rule of thumb, we recommend a
minimum of 10 hospitals or medical centers, with 15
preferable, and 20 ideal.
Analysis
The purpose of the analysis is to estimate the effect of the
receipt of the medical intervention, which is also called
method-effectiveness [16]. As derived by Baker and Lin-
deman [9][13], if the aforementioned requirements hold,
for each hospital or medical center, the estimated effect
of receipt of treatment is
D/F, where
D= difference in outcome before and after change in
availability
F = fraction that received intervention after change in
availability – fraction that received intervention before
change in availability
If the outcome measure is a continuous variable such as
blood measure, D is a difference in the average outcomes
between the "before" and "after" groups. If the outcome
measure is binary, such as success or failure, D is a dif-
ference in the fraction who fail or succeed in the "before"
and "after" groups.
The above estimate, D/F, has an analog in the analysis of
randomized trials when some subjects switch treatments
soon after randomization. With an intent-to-treat analy-
sis, one can estimate use-effectiveness, D*, which is the
effect of random assignment of treatment on outcome.
Similarly, one can estimate F*, the fraction of subjects in
the study group that received the new treatment minus
the fraction of subjects in the control group that received
the new treatment. Invoking an assumption analogous to
the fifth requirement for the paired availability design,
the estimated method-effectiveness is D*/F* [17].
As illustrated in the calculations accompanying Table 3,
we use a standard approach for a random effects meta-
analysis [19] to summarize the estimated effect of receipt
of treatment over all studies. The summary statistic is a
weighted average of the estimated effect of receipt of
treatment for each hospital or medical center, where the
weight for each hospital or medical center is the recipro-
cal of the sum of the sampling variance and the variance
of the true effect over the studies. The sampling varianceBMC Medical Research Methodology 2001, 1:9 http://www.biomedcentral.com/1471-2288/1/9
of the estimated effect of receipt of treatment, the varia-
bility due to taking a sample from a hypothetical larger
population, approximately equals the sampling variance
of the numerator, which is a standard calculation, divid-
ed by denominator squared. The variability of the true ef-
fect, which arises because the medical intervention is not
exactly identical among all hospitals, is computed using
the formula in DerSimonian and Laird [19]. The stand-
ard error of the summary statistic is the square root of
the reciprocal of the sum of the weights. An approximate
95% confidence interval is computed as the summary
statistic plus or minus the standard error multiplied by
the 97 1/2 percentile of a t-distribution with degrees of
freedom equal to the number of hospitals or medical
centers minus one [20]. This value can be found in tables
in many statistics books; for example for 11 hospitals,
there are 10 degrees of freedom and the value is 2.23.
Example
Baker and Lindeman applied the paired availability de-
sign to study the effect of epidural analgesia on the prob-
ability of Cesarean section [9]. They identified 11
hospitals or medical centers where epidural analgesia
was introduced, expanded, or discontinued. Stable pop-
ulation and stable treatment requirements were sup-
ported by the reports of the investigators. Stable
evaluation held because of the unambiguous nature of
the outcome. The stable preference requirement likely
held, as there were no widely published reports concern-
ing risks or benefits of epidural analgesia and no direct-
to-consumer advertising of the procedure. Because in-
creased availability would likely cause some subjects to
receive epidural analgesia earlier in the course of labor,
there was concern about violating the fifth requirement
of no effect of availability on the effect of intervention.
However, because a randomized trial had previously
shown that the effect of epidural analgesia on the proba-
bility of Cesarean section did not differ whether epidural
analgesia was initiated early or late in labor, the require-
ment was thought to hold. A slightly simplified version of
the data from Baker and Lindeman [9] is given in Table
3. In particular, to simplify the calculations for the hos-
pital designated as number 11, we regrouped data from
multiple time periods into two time periods.
Using the aforementioned method of analysis, with more
details in the notes for Table 3, the estimated increase in
the probability of Cesarean section due to epidural anal-
gesia was -0.005 with a 95% confidence interval of (-
.047, .037). This is fairly close to the more exact calcula-
tions based on a permutation distribution in [9]. Impor-
tantly, these results were similar to those from a meta-
analysis of randomized trials adjusted for switching of
treatments that yielded an estimate of method effective-
ness of .02 with 95% confidence interval of (-.02, .08)
[9]. In contrast, a high quality propensity score analysis
of cohort data gave a much larger estimate of. 10 with a
95% confidence interval of (.07, .13). The bias may be due
to the omission of a risk factor for intense pain early in
labor [9].
Discussion
The paired availability design has promise for evaluating
medical versus surgical interventions. For such an evalu-
ation, it would be difficult to recruit patients to a rand-
omized trial because few patients want to be randomized
to those options. Also, many physicians feel uncomforta-
ble assigning their patients to invasive versus non-inva-
sive interventions. Thus a validated alternative method
of evaluation would be of considerable value. We think
that, in some cases, the paired availability design would
be well suited for this type of evaluation. The key to the
stable population requirement is having clear and con-
stant eligibility criteria. For stable treatment, ancillary
care and the method of evaluation must be the same over
time. For the stable preference assumption to hold, there
should be no advertising of the medical intervention. For
the requirement of no effect of availability on the effect of
intervention, either the surgical technique should have
stabilized or the design should only include hospitals
with no previous surgeries.
A possible example would be an analysis of surgical re-
moval of liver metastases in patients with colorectal can-
cer. Although liver metastatectomy has been associated
with favorable outcomes, a more rigorous evaluation is
needed. An analysis of prospective cohort data is likely to
be biased because of the difficulty observing or quantify-
ing important risk factors such as patient performance
status, tumor doubling times, and meticulous staging.
Several conditions listed in Table 2 are favorable to a
paired availability design. The surgical approach has
been relatively stable for years. The use of CT scans and
CEA blood testing in follow-up of patients after resection
of the primary tumor has been popular for at least two
decades. Although systemic therapy has changed, effica-
cy of chemotherapy for metastatic disease has reached a
plateau. Metastatectomy is not one of the procedures
heavily advertised by hospitals or medical centers. An
ideal circumstance would be to apply the paired availa-
bility design to hospitals before and after the arrival of a
surgical oncologist who brings the procedure into com-
mon practice for the first time at that hospital.
A well-designed randomized study of liver metastatecto-
my would still give a more statistically valid assessment
of the procedure than the paired availability design.
However, such a randomized study has never been done,
despite the use of metastatectomy for many years. ABMC Medical Research Methodology 2001, 1:9 http://www.biomedcentral.com/1471-2288/1/9
paired availability design would likely be subject to fewer
biases than a cohort study comparing outcomes of pa-
tients who did versus those who did not undergo the sur-
gical procedure.
To decide if a method for analyzing observational data is
generally reliable, one should have experience compar-
ing the results to those obtained from a randomized trial.
In the only application of the paired availability design to
date. Baker and Lindeman obtained similar results from
the paired availability design as from a meta-analysis of
randomized trials. These results differed substantially
from a multivariate adjustment for concurrent controls,
which likely omitted an important risk factor2. Hopefully
this article will spur new studies using the paired availa-
bility design, including some comparing the results to
those from randomized trials.
Conclusion
We wish to emphasize that the randomized trial repre-
sents the strongest form of evaluation and should be im-
plemented if possible. However we recognize that there
are situations where the randomized trial is difficult to
implement, such as comparing medical versus surgical
interventions. If the requirements for the paired availa-
bility design are met, we recommend it as an alternative
with advantages over the usual analyses from observa-
tional studies.
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